Lv, M., Wang, L., Mingkun, W., Zhao, T., Pei, X., Mo, X., Sun, Y., Zhang, X., Kuang, N., Huang, X., Zhao, X. (2026). First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6508